Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) at the human blood-brain barrier (BBB)

Martin Bauer, Cecile Philippe, Rudolf Karch and Oliver Langer
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1747;
Martin Bauer
1Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecile Philippe
2Nuclear Medicine, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudolf Karch
3Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Langer
1Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1747

Objectives The adenosine triphosphate-binding cassette transporters Pgp and BCRP are 2 major gatekeepers at the BBB which restrict brain distribution of several drugs. In this study we investigated the suitability of the radiolabeled Pgp/BCRP inhibitors 11C-tariquidar and 11C-elacridar to assess Pgp density in human brain with PET.

Methods Healthy subjects underwent a first PET scan of 120 min duration with either 11C-tariquidar (n = 6) or 11C-elacridar (n = 5) followed by a second PET scan of 60 min duration with (R)-11C-verapamil. During scan 1 (at 60 min after radiotracer injection) unlabeled tariquidar (3 mg/kg) was intravenously administered. The kinetic model describing best tracer BBB transport was investigated.

Results Following injection of 11C-tariquidar or 11C-elacridar, brain PET signal corrected for radioactivity in vasculature was yery low (~0.1 SUV) with slow washout. In response to tariquidar injection, a moderate rise in brain PET signal was observed for 11C-tariquidar (+27±15%, P=0.01 paired t-test) and 11C-elacridar (+21±15%, P=0.01) without changes in plasma activity concentrations and low levels of radiolabeled metabolites (<25%) for both tracers at 60 min after injection. The 2T4K model provided best data fits. There was no significant correlation between distribution volumes (VT) of 11C-tariquidar or 11C-elacridar and VTs of (R)-11C-verapamil in different brain regions.

Conclusions The in vivo behavior of 11C-tariquidar and 11C-elacridar was consistent with that of dual Pgp/BCRP substrates. Tracers were unable to visualize cerebral Pgp density, most likely related to insufficiently high binding affinities in relation to the very low density of Pgp in human brain. Both new tracers may find use as a new class of radiotracers to study the interplay of Pgp and BCRP at the human BBB in limiting brain uptake of dual substrates.

Research Support European Community’s FP7/2007-2013 (201380) and Austrian Science Fund project ‘‘Transmembrane Transporters in Health and Disease’’ (SFB F35)

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) at the human blood-brain barrier (BBB)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) at the human blood-brain barrier (BBB)
Martin Bauer, Cecile Philippe, Rudolf Karch, Oliver Langer
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1747;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) at the human blood-brain barrier (BBB)
Martin Bauer, Cecile Philippe, Rudolf Karch, Oliver Langer
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 1747;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • PET CT Quantification to direct Alzheimer’s patients to anti-amyloid therapy
  • Multicenter trial study for usefulness of physical parameters toward the standardization of brain SPECT image: relation to visual analysis
  • Assessment of Brain Perfusion 123I-IMP SPECT imaging Using Low Energy High Resolution Collimator image reconstructed by Flash 3D
Show more Neurosciences

MTA II: Basic Science (Neurosciences) Posters

  • PET CT Quantification to direct Alzheimer’s patients to anti-amyloid therapy
  • Multicenter trial study for usefulness of physical parameters toward the standardization of brain SPECT image: relation to visual analysis
  • Assessment of Brain Perfusion 123I-IMP SPECT imaging Using Low Energy High Resolution Collimator image reconstructed by Flash 3D
Show more MTA II: Basic Science (Neurosciences) Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire